Vaccines and antibodies in Alzheimer´s disease
(drug classes)
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
Autoantibodies are now attracting significant interest in the AD field, with more than twenty types identified and studied, notably relating to Abeta. The presence of autoantibodies in AD patients is highly relevant to the current immunotherapeutic pipeline (vaccines and therapeutic antibodies) being developed to target this disease. As well as their diagnostic significance, autoantibodies may also give insights into new treatment strategies. The immune system is able to respond to antigens that are present at only very low levels in the body – therefore, the characterisation of AD-related antigens and their respective antibodies may allow detection of changes that occur early in the development of AD. New technologies, such as the peptoid combinatorial platform being developed by OPKO Health, offer new and more rapid advances in this field. This report discusses findings on AD-related autoantibodies in relation to the current pipeline of vaccines and therapeutic antibodies. Continue to read: pr-inside.com
A powerful new antioxidant